Aims: To determine the pattern of c-myc oncogene expression in anal squamous neoplasia and to determine ifthis could be used as a marker of disease progression. Methods: The presence and localisation of the c-myc gene product p62 in archival specimens of anal squamous epithelium, normal and neoplastic, was examined using immunohistochemical staining with the monoclonal antibody Mycl-6E10. Ten normal anal epithelia, 10 anal intraepithelial neoplasia (AIN) III, and 31 anal squamous cancers were examined. Results: There was a noticeable difference between the staining characteristics of invasive tumours, normal anal epithelium, and AIN III. Intense, diffuse, mixed nuclear and cytoplasmic (n = 14) and exclusively nuclear (n = 8) staining in 22 of 31 (71%) of invasive anal tumours was observed. All positively staining tumours were well differentiated histologically, while the negatively staining nine of31 (29%) were poorly differentiated (n= 7) and moderately well differentiated (n = 2). In six positively staining tumour sections adjacent areas of AIN III and non-dysplastic anal epithelium had staining characteristics similar to those of the invasive component. Staining in both normal anal epithelium (4/10) and AIN III specimens obtained from patients without a history of invasive disease (8/10) was less intense, focal in distribution, and exclusively nuclear. No difference in staining characteristics could be detected in these two groups.
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Conclusions: The results of this study suggest that c-myc oncogene expression is implicated in the pathogenesis of anal squamous neoplasia, and that immunohistochemical staining for c-myc protein may be helpful in identifying those AIN III lesions most likely to progress to invasive tumours.
(_f Clin Pathol 1993;46: [23] [24] [25] [26] [27] Cellular oncogenes or proto-oncogenes are a group of regions that have been conserved on the normal genome and which are the cellular homologues of retroviral genes with transforming ability.' 2 These genes and their protein products are thought to have an important role in early development.3 They may also be involved in the control of cellular growth,4 differentiation,5 and tissue repair processes.6 A change in the coding or controlling regions of these genes by a variety of mechanisms, such as gene amplification, translocation, and mutation have been implicated in the pathogenesis of malignant transformation in several different human tumours.' [7] [8] [9] [10] Cellular myc (c-myc) oncogene was first identified as a homologue of the transforming sequence of MC29, the avian myelocytomatosis virus," and has been found to be amplified in a wide variety of human cancer lines including small cell lung carcinoma,7 12 breast cancers,'3 and COLO 320 carcinoma"4 as well as in fresh human tumours.'5 16 In addition, a significant number of colon carcinomas have also been shown to overexpress the c-myc gene in the absence of gross genetic changes at the locus, suggesting that deregulation of the c-myc gene may occur by mechanisms other than gene alteration. 17 Several studies have shown that c-myc is overexpressed due to amplification or rearrangement of the gene and increased messenger RNA and protein product stability in different grades of cervical intraepithelial (CIN) and cervical squamous cell carcinomas. 9 18 Overexpression has been shown to have prognostic importance.20 The present study addresses the presence and localisation of the c-myc protein in normal anal epithelium, high grade anal intraepithelial neoplasia (AIN), and anal squamous cancer, using a monoclonal antibody directed against the c-myc protein-p62. Monoclonal antibodies directed against this epitope have already been used successfully in immunohistochemical evaluation of cervical,8 21 The staining technique used is a modification of the labelled avidin-biotin horseradish peroxidase technique25 using the Dako quick staining labelled streptavidin-biotin-avidin kit (Dako LSAB; Dako Ltd, Buckinghamshire, England). Endogenous peroxidase was blocked by a five minute incubation in 3% hydrogen peroxide. The sections were washed briefly with distilled water and sequentially incubated for 30 minutes each in prediluted non-immune goat serum (Dako LSAB kit) as a blocking agent to minimise non-specific binding, mouse monoclonal antibody Mycl-6E10 (Cambridge Research Biochemical, Cheshire, England) used in a 1 in 300 dilution (6 ng/ml) in phosphate buffered saline with 0O 1% sodium azide and 0-1% triton X-100 (pH 7 2), prediluted biotinylated anti-mouse secondary antibody (Dako kit), and peroxidase conjugated streptavidin (Dako LSAB) which was diluted with 0 05MTRIS/HCI buffer (pH 7-6) and freshly prepared according to the manufacturer's instructions.
Washing in TRIS-buffered saline (pH 7-6) was carried out after each incubation, and following the final washing in TRIS-buffered saline, the peroxidase reaction was developed by application of DAB solution (1 mg/ml diaminobenzidine in 0-05M TRIS/HCI buffer activated with 7 5 ml 10 vol H202 immediately before use). The 21 24 although its precise role in the neoplastic process is unknown. There is evidence of progression of c-myc overexpression from normal tissues through preinvasive lesions to invasive tumours in some tissues.18 22 23 Several mechanisms have been Our results show that p62 is strongly expressed in well differentiated invasive anal squamous tumours. Importantly, in areas of AMN III and non-dysplastic squamous epithelium adjacent to invasive tumour, the staining characteristics were similar to those of the invasive component-a field effect. This is in contrast to the staining pattern in normal anal epithelium and AIN III specimens obtained from patients in whom there is no evidence of invasive disease. In these groups expression of c-myc protein was less intense, involving isolated scattered cells mainly in the basal epithe- anal cancer. These results suggest that c-myc oncogene overexpression may be implicated in the pathogenesis of anal neoplasia and that AIN III may be premalignant. The apparent decline of c-myc expression with poorly differentiated tumours is similar to that seen in colorectal and testicular tumours24 38 and would also be consistent with a role for the gene product in cellular differentiation. The results of this study are similar to those obtained in two previous studies investigating the status of c-myc in invasive anal squamous neoplasia: they implicate deregulation of the c-myc oncogene in the pathogenesis of anal neoplasia. The first study39 showed amplification of the c-myc locus in only 30% of 50 anal cancers and in no cases of AIN III or those with normal anal epithelium. This suggested that deregulation of c-myc occurred late in the neoplastic process. The second study also showed pronounced c-myc amplification in 25 of 31 (80%) anal squamous tumours compared with no amplification in normal anal epithelium.40 Our study is the first to suggest that deregulation of the c-myc gene may occur earlier in the pathogenesis of anal squamous neoplasia. Larger studies are required to confirm these results. Twelve of the tumours examined in our study have been analysed for c-myc amplification by DNA hybridisation.40 Eight of these tumours were well differentiated histologically and stained positively for p62 c-myc in the present study, had marked amplification of the c-myc locus, (table 2) showing a good correlation (66-6%) between c-myc amplification and expression. However, two tumours which stained positively for p62 did not demonstrate amplification, suggesting that mechanisms other than gene amplification may result in c-myc deregulation. Increased mRNA and protein stability and proviral insertion (acting as trans or cis activators) may be responsible. Two poorly differentiated tumours which were negative for p62 did not demonstrate amplification at the c-nyc locus.
In conclusion, although this is a relatively small study, these results strongly suggest that c-myc oncogene expression is implicated in the pathogenesis of anal squamous neoplasia, and that immunohistochemical detection of c-myc protein (p62) may be useful in identifying those AIN III lesions likely to progress to invasive tumours. 
